GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity

NCT07668765 · Not yet recruiting

Last updated 2026-07-14

This clinical trial is testing whether GLP-1 receptor agonists, a type of medication, affect the development of proctologic conditions (such as hemorrhoids or anal fissures) in people with morbid obesity.

Status Not yet recruiting Approved but enrollment has not started.

Type Observational

Participants 100 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-08 · est. completion 2027-05

Where 1 site · Turkey (Türkiye)

What this study is testing ClinicalTrials.gov NCT07668765 ↗

Description as written by the study sponsor.

Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.

Treatments tested

GLP-1 receptor agonist therapy Drug

Participants will receive GLP-1 receptor agonist treatment as part of routine clinical care. The study does not assign treatment but prospectively evaluates proctologic outcomes following treatment initiation.

Main thing measured	Incidence of newly developed proctologic disease
Sponsor	Gazi University
Conditions studied	Morbid Obesity, Anorectal Diseases, Drug-Related Side Effects and Adverse Reactions, Constipation, Diarrhea
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07668765 ↗